*Based on commercial patients, early access patients, and clinical trial participants through May 2022.1
†SPINRAZA pivotal studies included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.2